EUCTR2011-001144-30-IT进行中（未招募）1 期
Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia A - Pathfinder™ 3
OVO NORDISK0 个研究点目标入组 53 人开始时间: 2012年8月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Informed consent obtained before any trial-related activities. (Trialrelated
- •activities are any procedure that would not have been performed
- •during normal management of the subject.)
- •- Ongoing participation in the pathfinderTM 2 (NN7088-3859) or the
- •pathfinderTM 4 (NN7088-3861) trial and having received =5 doses of
- •- Undergoing major surgery (refer to Section 5.3.1 for definition)
- •requiring daily monitoring of FVIII:C and wound status for =3 days
- •- The patient and/or Legally Acceptable Representative (LAR) is capable
- •of assessing a bleeding episode, keeping an eDiary, capable of home
- •treatment of bleeding episodes and otherwise capable of following the
- •trial procedures
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 2
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Known or suspected hypersensitivity to trial product including allergy
- •to hamster protein or related products
- •- Previous withdrawal from the pathfinderTM 2 (NN7088-3859) or the
- •pathfinderTM 4 (NN7088-3861) trial after administration of trial product,
- •except interruption due to inclusion in this pathfinderTM 3 trial
- •(NN7088-3860)
- •- The receipt of any investigational medicinal product (except N8-GP)
- •within 30 days prior to enrolment into the trial. (For Brazil, only:
- •Participation in a previous clinical trial within one year prior to screening
- •for this trial (Visit 1), unless there is a direct benefit to the research
- •subject, at the Investigator's discretion)
- •- FVIII inhibitors = 0.6 BU/mL at screening (refer to Section 8.1.1)
- •- Previous arterial thrombotic events (e.g. myocardial infarction and
- •intracranial thrombosis) or previous deep venous thrombosis or
- •pulmonary embolism (as defined by available medical records)
- •- Immune modulating or chemotherapeutic medication
- •- Any disease (liver, kidney, inflammatory and mental disorders
- •included) or condition which, according to the Investigator's judgement,
- •could imply a potential hazard to the patient, interfere with trial
- •participation or trial outcome
- •- Unwillingness, language or other barriers precluding adequate
- •understanding and/or cooperation
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia AEUCTR2011-001144-30-ESovo Nordisk A/S53
进行中（未招募）
1 期
Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia A - pathfinder™ 3EUCTR2011-001144-30-BGovo Nordisk A/S53
进行中（未招募）
1 期
Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia AEUCTR2011-001144-30-SEovo Nordisk A/S53
进行中（未招募）
1 期
Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia A - pathfinder™ 3EUCTR2011-001144-30-HUovo Nordisk A/S53
进行中（未招募）
1 期
Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia AHaemophilia AMedDRA version: 16.1 Level: LLT Classification code 10018937 Term: Haemophilia A System Organ Class: 100000004850EUCTR2011-001144-30-DKovo Nordisk A/S53